(:PGNX)

Business Focus: N/A

Jun 22, 2020 07:00 am ET

Lantheus Completes Merger with Progenics

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced that it has completed its previously announced merger with Progenics Pharmaceuticals, Inc. (“Progenics”) (Nasdaq: PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer. The merger agreement was first announced on October 2, 2019.

Jun 17, 2020 05:33 pm ET

Independent Bank Group Set to Join S&P SmallCap 600

NEW YORK, June 17, 2020 /PRNewswire/ -- Independent Bank Group Inc. (NASD: IBTX) will replace Progenics Pharmaceuticals Inc. (NASD: PGNX) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, June 22. S&P Small-Cap 600 constituent Lantheus Holdings Inc. (NASD: LNTH) is acquiring Progenics Pharmaceuticals in a deal expected to be completed on or about June 19 pending final conditions. Post-acquisition, Lantheus Holdings will remain in S&P SmallCap 600.

Jun 16, 2020 04:05 pm ET

Progenics Stockholders Approve Merger with Lantheus

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, announced that at a special meeting of its stockholders held earlier...

May 27, 2020 07:53 pm ET

SHAREHOLDER ALERT: WeissLaw LLP Investigates Progenics Pharmaceuticals, Inc.

NEW YORK, May 27, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company") (NASDAQ: PGNX) in connection with the proposed acquisition of the company by Lantheus Holdings, Inc. ("LNTH") (NASDAQ: LNTH). Under the terms of the acquisition agreement, PGNX shareholders will receive 0.31 shares of LNTH for each PGNX share they own, representing implied per-share merger consideration of only $3.96 based on LNTH's May 26, 2020 closing price of $12.77.

May 18, 2020 08:30 am ET

Progenics to Present Results from the Phase 3 CONDOR Trial of PyL™ (18F-DCFPyL) in Prostate Cancer at the American Society of Clinical Oncology 2020 Virtual Scientific Program

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that the results from the Phase 3 CONDOR trial evaluating the...

May 08, 2020 05:14 pm ET

Progenics Class Action: Halper Sadeh LLP Announces Filing Of Shareholder Class Action Lawsuit Against Progenics Pharmaceuticals, Inc.; Investors Are Encouraged To Contact The Firm

NEW YORK, May 8, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces the filing of a shareholder class action lawsuit against Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) in connection with the proposed merger between Progenics and Lantheus Holdings, Inc. The lawsuit seeks damages and/or equitable relief on behalf of Progenics shareholders under the federal securities laws.

May 07, 2020 07:30 am ET

Progenics Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced financial results for the first quarter 2020. “Progenics’ Board of Directors continues to believe the proposed merger with Lantheus under the revised terms is the best pathway forward...

Apr 23, 2020 08:09 pm ET

Faruqi & Faruqi, LLP Announces Filing of a Class Action Lawsuit Against Progenics Pharmaceuticals, Inc. (PGNX)

NEW YORK, April 23, 2020 /PRNewswire/ -- Notice is hereby given that Faruqi & Faruqi, LLP has filed a class action lawsuit in the United States District Court for the Southern District of New York, Case No. 1:20-cv-02847 on behalf of shareholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company") (NASDAQ:PGNX) who have been harmed by Progenics' and its board of directors' (the "Board") alleged violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") in connection with the proposed merger of the Company with Lantheus Holdings, Inc.

Apr 23, 2020 08:30 am ET

Progenics Pharmaceuticals Sets First Quarter 2020 Financial Results and Business Update Call for May 7

Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that it will host a conference call and webcast to review first...

Apr 14, 2020 11:17 am ET

ADDING MULTIMEDIA Velan Capital Agrees to Support Merger of Lantheus and Progenics

Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that Lantheus has entered into a Support Agreement (the “Support Agreement”) with Velan Capital (“Velan”) in connection with the proposed merger of Lantheus and Progenics.

Apr 14, 2020 09:00 am ET

Velan Capital Agrees to Support Merger of Lantheus and Progenics

Mar 13, 2020 08:30 am ET

PROGENICS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced financial results for the fourth quarter and full-year 2019. “The recent positive top line results from the Phase 3 CONDOR trial of PyL™ highlights the potential of our...

Feb 20, 2020 11:30 am ET

Lantheus and Progenics Agree to Amended Transaction Terms

Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that they have entered into an Amended and Restated Agreement and Plan of Merger (the “Amended Agreement”) which amends the previously announced definitive Agreement and Plan o

Feb 06, 2020 08:30 am ET

Progenics Pharmaceuticals Announces Presentations at the 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium Annual Meeting (ASCO GU)

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that three abstracts highlighting PyLTM (18F-DCFPyL), I-131...

Jan 21, 2020 04:15 pm ET

Progenics Pharmaceuticals Provides Update on Reconstituted Board’s Ongoing Strategic Review

The Board of Directors of Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, issued the following letter to shareholders:...

Jan 16, 2020 09:10 am ET

Progenics Pharmaceuticals Announces Presentation at the 2020 SNMMI Mid-Winter Meeting

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that an abstract highlighting data from its PSMA AI program...

Jan 06, 2020 05:48 pm ET

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Progenics Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Progenics Pharmaceuticals, Inc. (“Progenics” or “the Company”) (NASDAQ:

Dec 23, 2019 07:00 am ET

Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL™ in Prostate Cancer Achieved Primary Endpoint

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced positive top line results from the Phase 3 CONDOR trial...

Dec 22, 2019 05:00 pm ET

Progenics Pharmaceuticals to Announce and Host a Conference Call to Discuss Top Line Results from Phase 3 CONDOR Trial of PyL™ in Prostate Cancer on Monday, December 23rd

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that it will host a conference call to review the top line...

Dec 20, 2019 03:00 pm ET

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Progenics Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Dec 12, 2019 01:19 pm ET

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of the Following Mergers

Rigrodsky & Long, P.A. announces that it is investigating: Progenics Pharmaceuticals, Inc. (NASDAQ GS: PGNX) regarding possible breaches of fiduciary duties and other violations of law related to Progenics’ agreement to be acquired by Lantheus...

Dec 10, 2019 11:44 am ET

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – AXE, CISN, IPHS, PGNX

Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Anixter International Inc. (NYSE: AXE) The investigation concerns whether Anixter and its board of directors violated the federal securities...

Dec 04, 2019 08:00 am ET

INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – AMTD, TIF, MDCO, PGNX

Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: TD Ameritrade Holding Corporation (NASDAQ: AMTD)The investigation concerns whether TD Ameritrade and its board of directors violated the federal...

Nov 25, 2019 08:30 am ET

Progenics Pharmaceuticals Announces Presentations at the Radiological Society of North America (RSNA) Annual Meeting

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that four abstracts highlighting PyL (¹⁸F-DCFPyL) have been...

Nov 21, 2019 04:05 pm ET

Progenics Pharmaceuticals Appoints David Mims as Interim Chief Executive Officer

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced its Board of Directors has appointed David W. Mims as interim...

Nov 08, 2019 04:05 pm ET

Progenics Pharmaceuticals Announces Delivery of Consents and Revocations to Independent Inspector of Elections

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that it has delivered all...

Nov 08, 2019 02:21 pm ET

Velan Receives Requisite Number of Written Consents to Reconstitute Majority of Progenics Board

Velan Capital, L.P. (together with the other members of its group, “Velan” or “we”), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”) (NASDAQ:PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today announced it has delivered written consents from the holders of more than 55% (and up to 65%) of the Company’s outstanding shares to remove CEO Mark Baker, Dr. David Scheinberg and Nicole Williams from the Board of Directors (the “Board”) and to elect all five Velan nominees – Gérard Ber, Eric Ende, Ann

Nov 07, 2019 08:00 am ET

Progenics Pharmaceuticals Announces Business Update And Third Quarter 2019 Financial Results

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) is providing a business update and has today announced financial results for the third quarter 2019. “We recently entered into a compelling transaction to combine Progenics with...

Nov 06, 2019 08:00 am ET

Progenics Reminds Shareholders that November 17 is the True Deadline for Velan’s Consent Solicitation

Nov 04, 2019 08:00 am ET

Glass Lewis Recommends Stockholders Vote on GREEN Consent Card for Velan Nominees to Constitute Majority of Progenics Board

Velan Capital, L.P. (together with the other members of its group, “Velan” or “we”), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”) (NASDAQ:PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today announced that a leading proxy advisory firm, Glass, Lewis & Co. (“Glass Lewis”), has recommended that stockholders vote on the GREEN consent card in support of Velan’s director nominees, Dr. Gérard Ber, Dr. Eric Ende, Heinz Mäusli and David Mims, to constitute a majority of the Progenics Board of Direct

Nov 04, 2019 08:00 am ET

Progenics Urges Shareholders to Reject the Risk and Uncertainty That Would be Caused by Giving Velan’s Nominees Control of the Board

Nov 01, 2019 01:00 pm ET

Progenics Reminds Shareholders that November 17 is the Only Deadline for Velan’s Consent Solicitation

Oct 28, 2019 02:00 pm ET

Progenics Strongly Agrees With ISS Recommendation that Velan Group SHOULD NOT Get Majority Control of the Board of Directors

Oct 28, 2019 07:00 am ET

ISS Recommends Shareholders Vote on the GREEN Consent Card for Election of Velan Nominees and Removal of Progenics CEO

Velan Capital, L.P. (together with the other members of its group, “Velan” or “we”), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”) (NASDAQ:PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today announced that a leading proxy advisory firm, Institutional Shareholder Services Inc. (“ISS”), has recommended that shareholders vote on the GREEN consent card in support of Velan’s director nominees, Dr. Gérard Ber, Dr. Eric Ende and David Mims.

Oct 24, 2019 02:05 pm ET

Independent Director Candidates Nominated by Velan Issue Letter to Progenics Shareholders

Today, Dr. Gérard Ber released an open letter to stockholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”) (NASDAQ:PGNX) on behalf of himself and the four other fully-independent director candidates – Dr. Eric J. Ende, Ann MacDougall, Heinz Mäusli and David W. Mims – nominated by Velan Capital, L.P. (“Velan”) for election to the Progenics Board of Directors (the “Board”).

Oct 23, 2019 05:03 pm ET

Velan Responds to Misleading Communications from Progenics

Velan Capital, L.P. (together with the other members of its group, “Velan” or “we”), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”) (NASDAQ:PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today responded to the Company’s presentation and press release, including misleading statements surrounding the Lantheus Medical Imaging, Inc. (“Lantheus”) merger agreement and interactions with the Progenics Board of Directors (the “Board”). Velan issued the following statement:

Oct 23, 2019 09:55 am ET

Progenics Highlights Additional Serious Concerns About Velan Capital, L.P.

Oct 22, 2019 09:00 am ET

Velan Sends Letter to Progenics Stockholders

Velan Capital, L.P. (together with the other members of its group, “Velan” or “we”), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”) (NASDAQ:PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today announced that it has sent a letter to fellow Progenics stockholders outlining the current Board’s failure to represent the best interests of stockholders, as most recently illustrated by the Company’s agreement to be acquired by Lantheus Medical Imaging, Inc. (“Lantheus”). The letter also highlights the

Oct 21, 2019 08:46 am ET

Progenics Sends Letter to Shareholders

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today issued the following letter that it intends to mail to shareholders,...

Oct 21, 2019 08:00 am ET

Velan Issues Presentation Outlining Nominees’ Comprehensive Strategic Plan to Save Progenics

Velan Capital, L.P. (together with the other members of its group, “Velan” or “we”), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”) (NASDAQ:PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today released a detailed presentation on Progenics. The presentation outlines the Company’s persistent underperformance and strategic failures and provides our Nominees’ comprehensive strategic plan to address key performance pitfalls, years of neglecting stockholders’ interests and egregious governance issue

Oct 17, 2019 01:58 pm ET

PGNX, PRTO, and ARTX SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers

Oct 15, 2019 10:12 am ET

Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders – RARX, PGNX, TSG, ROAN

Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Ra Pharmaceuticals, Inc. (NASDAQ: RARX)The investigation concerns whether Ra Pharmaceuticals and its board of directors violated the federal...

Oct 09, 2019 04:30 pm ET

Progenics Sends Letter to Shareholders

Oct 08, 2019 04:11 pm ET

SHAREHOLDER ALERT: WeissLaw LLP Reminds HLND, TNCB, PGNX, DOVA Shareholders About Its Ongoing Investigations

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP 1500 Broadway, 16th...

Oct 08, 2019 03:55 pm ET

Lifshitz & Miller LLP Announces Investigation of Arotech Corporation, Dova Pharmaceuticals, Inc., Highlands Bankshares, Inc., Progenics Pharmaceuticals, Inc., Proteon Therapeutics, Inc., Roan Resource

NEW YORK, Oct. 8, 2019 /PRNewswire/ --

Oct 08, 2019 08:00 am ET

Velan Sends Letter to Progenics Pharmaceuticals Stockholders and Files Definitive Consent Statement

Velan Capital, L.P. (together with the other members of its group, “Velan” or “we”), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”)(NASDAQ:PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today announced that it has sent a letter to fellow Progenics stockholders and filed a definitive consent statement with the Securities and Exchange Commission in connection with its solicitation of written consents from stockholders to reconstitute the Progenics Board of Directors through the removal of the th

Oct 04, 2019 06:14 pm ET

SHAREHOLDER ALERT: WeissLaw LLP Investigates Progenics Pharmaceuticals, Inc.

NEW YORK, Oct. 4, 2019 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company") (NASDAQ: PGNX) in connection with the proposed acquisition of the Company by Lantheus Holdings, Inc. ("LNTH") (NASDAQ: LNTH). Under the terms of the acquisition agreement, PGNX shareholders will receive 0.2502 shares of LNTH for each PGNX share they own, representing consideration of $4.76 based on LNTH's October 2 closing price.

Oct 03, 2019 05:50 pm ET

PROGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Progenics Pharmaceuticals, Inc. - PGNX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Progenics Pharmaceuticals, Inc. (NasdaqGS: PGNX) to Lantheus Holdings, Inc. (NasdaqGS: LNTH). Under the terms of the proposed transaction, shareholders of Progenics will receive only 0.2502 shares of Lantheus for each share of Progenics that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.

Oct 03, 2019 03:54 pm ET

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigations of Mergers

Rigrodsky & Long, P.A. announces that it is investigating: Highlands Bankshares, Inc. (OTC Pink: HLND) regarding possible breaches of fiduciary duties and other violations of law related to Highland’s agreement to be acquired by First Community...

Oct 03, 2019 12:14 pm ET

INVESTOR ALERT: Monteverde & Associates PC Announces an Investigation of the Following Merger

NEW YORK, Oct. 3, 2019 /PRNewswire/ --

Oct 03, 2019 11:26 am ET

Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Progenics Pharmaceuticals, Inc. has obtained a Fair Price in its sale to Lantheus Holdings, Inc.

MILWAUKEE, Oct. 3, 2019 /PRNewswire/ -- Ademi & O'Reilly, LLP is investigating Progenics (Nasdaq: PGNX) for possible breaches of fiduciary duty and other violations of the law in connection with the sale of Progenics to Lantheus.

Oct 03, 2019 10:52 am ET

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Progenics Pharmaceuticals, Inc. to Lantheus Holdings, Inc. is Fair to Shareholders

The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”) (NASDAQ: PGNX) stock prior to October 2, 2019. You are hereby...

Oct 02, 2019 05:04 pm ET

Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) on Behalf of Progenics Shareholders and Encourages Progenics Investors to Contact

NEW YORK, Oct. 2, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) on behalf of Progenics shareholders concerning the proposed merger with Lantheus Holdings, Inc.

Oct 02, 2019 02:25 pm ET

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Progenics Pharmaceuticals, Inc.

NEW YORK, Oct. 2, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Lantheus Holdings, Inc. (NASDAQ: LNTH). Stockholders will receive 0.2502 shares of Lantheus Holdings common stock for each share of Progenics Pharmaceuticals stock that they hold. The transaction is valued at approximately $412 million and is expected to close in the first quarter of 2020.

Oct 02, 2019 01:23 pm ET

Velan Comments on Announced Sale of Progenics to Lantheus

Velan Capital, L.P. (together with the other members of its group, “Velan” or “we”), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”)(NASDAQ:PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today responded to the decision by the Progenics Board of Directors (“Board”) to enter into a value-destructive all-stock transaction with Lantheus Holdings, Inc. (“Lantheus”) in the midst of Velan’s consent solicitation to reconstitute a majority of the Board:

Oct 02, 2019 11:17 am ET

Progenics Merger Investigation: Halper Sadeh LLP Announces Investigation into Whether the Sale of Progenics Pharmaceuticals, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) to Lantheus Holdings, Inc. (“Lantheus”) for 0.2502 shares of Lantheus stock for each share of Progenics stock...

Oct 02, 2019 07:08 am ET

Lantheus to Acquire Progenics to Form a Leading Precision Diagnostics Imaging and Therapeutics Company

Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced a definitive agreement for Lantheus to acquire Progenics in an all-stock transaction. The transaction has been unanimously approved by the Boards of Directors of both companies

Sep 18, 2019 04:59 pm ET

Progenics Confirms Notice of Preliminary Consent Solicitation by Velan Capital, L.P. Despite Repeated Efforts by the Company to Reach a Reasonable Resolution

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today confirmed that Velan Capital, L.P. (“Velan”) filed with the U.S....

Sep 18, 2019 08:55 am ET

Velan Launches Consent Solicitation to Reconstitute the Progenics Board With Its Five Highly-Qualified, Independent Director Nominees

Velan Capital, L.P. (together with the other members of its group, “Velan” or “we”), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (“Progenics” or the “Company”)(NASDAQ:PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today announced that it has filed a preliminary consent statement with the SEC and delivered a written consent to the Company seeking to reconstitute the Progenics Board of Directors (“Board”) through the removal of the three long-tenured directors and the election of its five highly-qualified, fully-independen

Sep 03, 2019 08:30 am ET

Progenics Pharmaceuticals Announces Presentation at the International Conference on Immunotherapy Radiotherapy Combinations

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that an abstract highlighting PyLTM (18F-DCFPyL) has been...

Aug 12, 2019 08:00 am ET

Velan Highlights Progenics Pharmaceuticals' Continued Mismanagement Following Q2 2019 Earnings Results

ALPHARETTA, Ga., Aug. 12, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other members of its group, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ: PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today announced its disappointment with the Company's Q2 2019 results and lack of metrics to track future performance, and highlights key issues that illustrate the Company's continual mismanagement under the troubling status quo.

Aug 09, 2019 07:30 am ET

Progenics Pharmaceuticals Announces Second Quarter 2019 Financial Results and Business Update

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced financial results for the second quarter 2019 and provided a business update. “We are excited to report significant progress across our entire portfolio, with commercial, clinical, and...

Aug 08, 2019 08:00 am ET

Progenics Pharmaceuticals Announces Additional Governance Enhancements

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced a number of additional governance enhancements in response to...

Aug 06, 2019 08:30 am ET

CMS Grants New Technology Add-On Payment for Inpatient Use of AZEDRA® (iobenguane I 131)

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that the Centers for Medicare & Medicaid Services (CMS) has...

Aug 05, 2019 08:30 am ET

Progenics Pharmaceuticals Completes Enrollment in Pivotal Phase 3 CONDOR Study of PyL for the Detection of Prostate Cancer

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that it has completed enrollment five months ahead of schedule...

Aug 01, 2019 08:30 am ET

Progenics Pharmaceuticals Sets Second Quarter 2019 Financial Results and Business Update Call for August 9

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that it will host a conference call and webcast to review...

Jul 25, 2019 08:30 am ET

Progenics Pharmaceuticals Announces Collaboration with Veterans Affairs on the AI Research Program for Medical Image Analysis

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging technology for targeting and treating cancer, announced their collaboration with the VA Greater Los Angeles Healthcare System (VAGLAHS)...

Jul 22, 2019 08:00 am ET

Velan Announces Progenics Pharmaceuticals Stockholders Support its Campaign for Change at Progenics' 2019 Annual Meeting

ALPHARETTA, Ga., July 22, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other members of its group, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ: PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today announced that the final results of Progenics' 2019 Annual Meeting of Stockholders (the "Annual Meeting") confirm that stockholders have endorsed Velan's campaign for change at Progenics by voting against the re-election of Peter Crowley and Michael Kishba

Jul 17, 2019 07:41 pm ET

Court Upholds The Validity And Determined Actavis' Infringement Of Patent Protecting RELISTOR® Tablets

BRIDGEWATER, N.J. and NEW YORK, July 17, 2019 /CNW/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") and Progenics Pharmaceuticals (NASDAQ: PGNX), announced today that the U.S. District Court of New Jersey upheld the validity and determined Actavis' infringement of a patent protecting RELISTOR® (methylnaltrexone bromide) tablets, expiring March 2031.

Jul 17, 2019 07:41 pm ET

Court Upholds The Validity And Determined Actavis' Infringement Of Patent Protecting RELISTOR® Tablets

BRIDGEWATER, N.J. and NEW YORK, July 17, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") and Progenics Pharmaceuticals (NASDAQ: PGNX), announced today that the U.S. District Court of New Jersey upheld the validity and determined Actavis' infringement of a patent protecting RELISTOR® (methylnaltrexone bromide) tablets, expiring March 2031.

Jul 12, 2019 09:11 am ET

Progenics Announces Preliminary Voting Results of Annual Meeting of Shareholders

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that, based on the preliminary voting results of its 2019...

Jul 08, 2019 08:30 am ET

Progenics Urges Shareholders to Vote Today “FOR” the Highly Qualified Director Candidates on the WHITE Proxy Card

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, encourages all shareholders to vote today “FOR” all of the Board’s highly...

Jul 08, 2019 08:00 am ET

Velan Reminds Stockholders to Follow ISS' Recommendation by Voting "Against" Progenics Pharmaceuticals Directors Peter Crowley and Michael Kishbauch

ALPHARETTA, Ga., July 8, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ:PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today issued a statement urging stockholders to follow the recommendation of Institutional Shareholder Services Inc. ("ISS"), a leading independent proxy advisory firm, by voting AGAINST the election of Progenics directors Peter Crowley and Michael Kis

Jul 08, 2019 07:30 am ET

Progenics Pharmaceuticals Strengthens Management Team with Appointment of Huw Jones as Vice President, Commercial

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced the appointment of Huw Jones to the newly created role of Vice...

Jul 01, 2019 08:00 am ET

Velan Urges Stockholders To Follow ISS' Recommendation By Voting "Against" Progenics Pharmaceuticals Directors Peter Crowley And Michael Kishbauch

ALPHARETTA, Ga., July 1, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ: PGNX), comprised of successful specialty pharmaceutical operators and financial services experts, today issued a statement reminding stockholders that now is the time to demand accountability at Progenics and to follow the recommendation of Institutional Shareholder Services Inc. ("ISS"), a leading independent proxy advisory firm, by voting AGAINS

Jul 01, 2019 07:00 am ET

Leading Independent Proxy Advisory Firm Glass Lewis Recommends Progenics Shareholders Vote “FOR” ALL of Progenics’ Director Nominees

Jun 28, 2019 10:30 am ET

Progenics Reiterates Targeted Directors’ Indispensable Experience and Leadership Critical to the Company’s Long-Term Success

Jun 27, 2019 09:00 pm ET

Progenics Pharmaceuticals Details Recent Good Faith Efforts to Settle with Velan Capital

Jun 25, 2019 08:30 am ET

Data Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting Highlights Potential of Progenics’ PSMA-Targeted Imaging Agent, PyL, in Detecting Prostate Cancer

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that results from studies highlighting the PSMA-targeted...

Jun 24, 2019 08:30 am ET

Independent Readers Using Progenics’ PSMA AI Demonstrated a Statistically Significant Improvement of Accuracy, Speed, and Reproducibility Over Readers Without PSMA AI

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that results from a study evaluating the diagnostic...

Jun 24, 2019 08:00 am ET

Progenics Pharmaceuticals Files Supplemental Investor Presentation Rebutting Velan’s Latest Inaccurate Claims

Jun 20, 2019 08:30 am ET

Progenics Pharmaceuticals to Initiate a Basket Trial by Year End to Support an Expanded Label for AZEDRA® (iobenguane I 131) in Multiple MIBG Avid Neuroendocrine Tumors

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that the Company has reached...

Jun 19, 2019 08:30 am ET

Progenics to Mail Letter to Shareholders

Jun 18, 2019 09:05 am ET

Progenics Pharmaceuticals Announces Agreement with FUJIFILM Toyama Chemical Co. for Automated Bone Scan Index (aBSI) Product in Japan

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight, and follow cancer, today announced that EXINI, a wholly owned subsidiary of Progenics, has entered into a...

Jun 13, 2019 05:00 pm ET

Progenics to Mail Letter to Shareholders

Jun 13, 2019 08:30 am ET

Progenics Pharmaceuticals Doses First Patient in Phase 2 Clinical Study of 1095 Radiotherapy for the Treatment of Metastatic Prostate Cancer

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that the first patient has been dosed in the Company’s Phase 2...

Jun 06, 2019 07:45 am ET

Progenics Pharmaceuticals Announces Presentations at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced today announced that six abstracts highlighting AZEDRA...

Jun 03, 2019 08:30 am ET

Progenics Announces Updated Survival Data for AZEDRA® (iobenguane I 131) in Advanced Pheochromocytoma and Paraganglioma

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, announced today that long-term follow up data from its pivotal Phase 2 study...

Jun 03, 2019 08:00 am ET

Progenics Pharmaceuticals Mails Letter to Shareholders

May 30, 2019 08:30 am ET

Progenics Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that Mark R. Baker, Chief Executive Officer, will present at...

May 23, 2019 08:30 am ET

Progenics Pharmaceuticals Announces Presentations at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that four abstracts highlighting AZEDRA (iobenguane I 131) and...

May 22, 2019 08:30 am ET

Velan Files Definitive Proxy Materials in Connection with Progenics Pharmaceuticals 2019 Annual Meeting of Stockholders

ALPHARETTA, Ga., May 22, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics" or the "Company")(NASDAQ:PGNX), announced today that it has filed definitive proxy materials, including a GREEN proxy card, urging Progenics stockholders to vote AGAINST the re-election of Peter Crowley and Michael Kishbauch to the Progenics Board of Directors (the "Board") at the Company's 2019 Annual Meeting of Stockholders (the "Annual Meeting"). Velan also announced th

May 14, 2019 08:30 am ET

Progenics Pharmaceuticals and ROTOP Pharmaka GmbH Announce European Collaboration for Prostate Cancer Imaging Agent 1404

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, and ROTOP Pharmaka GmbH, a leading radiopharmaceuticals company focused on...

May 13, 2019 08:30 am ET

Velan Implores for Improved Transparency and Real Change at Progenics Pharmaceuticals Following Q1 2019 Earnings Call

ALPHARETTA, Ga., May 13, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with its affiliates, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics", "you" or the "Company")(NASDAQ:PGNX), today publicly called on the Company's management team and Board of Directors (the "Board") to increase the level of disclosure and transparency to stockholders given its apparent failure to do so in the Company's first quarter 2019 earnings call held on May 9, 2019.

May 09, 2019 07:45 am ET

Progenics Pharmaceuticals Announces First Quarter 2019 Financial Results and Business Update

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced financial results for the first quarter 2019 and provided a business update. “We are excited to report that the U.S. commercial launch of AZEDRA for the treatment of advanced or...

May 08, 2019 02:30 pm ET

Velan Calls for Increased Transparency at Progenics Pharmaceuticals During Q1 Earnings Call

ALPHARETTA, Ga., May 8, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with its affiliates, "Velan" or "we"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. ("Progenics", "you" or the "Company")(NASDAQ: PGNX), today publicly called on the Company's management team and Board of Directors (the "Board") to increase the level of disclosure and transparency when Progenics reports first quarter results on May 9, 2019. Velan also announced that it filed a preliminary proxy statement and accompanying GREEN proxy card yesterday seeking stockholder support against the election

May 07, 2019 04:15 pm ET

Progenics Pharmaceuticals Comments on Velan Capital’s Preliminary Proxy Statement

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX, “Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today issued the following statement regarding...

May 06, 2019 04:15 pm ET

Progenics Pharmaceuticals Issues Statement Regarding Velan Capital

May 06, 2019 08:30 am ET

Data Presented at the 2019 American Urological Association (AUA) Annual Meeting Showcases Potential for Progenics’ PyL Imaging Agent

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that data highlighting the potential of its PyL imaging agent...

May 06, 2019 08:30 am ET

Velan Delivers Letter to the Board of Progenics Pharmaceuticals

ALPHARETTA, Ga., May 6, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with its affiliates, "Velan"), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (the "Company")(NASDAQ: PGNX), today announced that it has delivered a letter to the Board of Directors (the "Board") of the Company expressing its concerns with the Company's persistent underperformance and poor corporate governance practices and stating its intent to hold certain members of the Board accountable at the Company's 2019 Annual Meeting of Stockholders.

May 02, 2019 08:30 am ET

Progenics Pharmaceuticals Sets First Quarter 2019 Financial Results and Business Update Call for May 9

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that it will host a conference call and webcast to review...

Apr 24, 2019 08:30 am ET

Results from Clinical Trial Show Progenics’ PyL (18F-DCFPyL) PSMA PET/CT Imaging Agent Changes Management Plans for More Than 87% of Patients

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that an analysis of an ongoing investigator-initiated study of...

Apr 08, 2019 07:50 am ET

Market Trends Toward New Normal in Trinity Industries, Progenics Pharmaceuticals, National CineMedia, Sykes Enterprises, Tennant, and CyberOptics — Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Trinity Industries, Inc. (NYSE:TRN), Progenics Pharmaceuticals Inc....

Apr 03, 2019 05:05 pm ET

Progenics Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that Mark R. Baker, Chief Executive Officer, will present at...

Apr 03, 2019 05:00 pm ET

Progenics Pharmaceuticals Announces Presentations at the 2019 American Urological Association (AUA) Annual Meeting

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that two abstracts featuring data from the Company’s PSMA...

Mar 14, 2019 07:45 am ET

Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2018 Financial Results and Business Update

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced financial results for the fourth quarter and full-year 2018 and provided a business update. “2018 was an extremely productive year for the advancement of our portfolio of...

Mar 14, 2019 07:40 am ET

Progenics Asserts Ownership of PSMA-617 Intellectual Property, Including Composition of Matter Patent

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that it has asserted...

Mar 11, 2019 08:30 am ET

Progenics Pharmaceuticals Announces Presentation of Safety Data for AZEDRA® (iobenguane I 131) at the 2019 Endocrine Society (ENDO) Annual Meeting

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that safety data from a pooled analysis of all available clinical...

Mar 07, 2019 08:30 am ET

Progenics Pharmaceuticals Sets Fourth Quarter and Full-Year 2018 Financial Results and Business Update Call for March 14

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that it will host a conference call and webcast to review fourth...

Feb 11, 2019 08:30 am ET

Progenics Acquires AZEDRA® (iobenguane I 131) Radiopharmaceutical Manufacturing Facility

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that it has acquired the Somerset, NJ manufacturing facility for...

Jan 22, 2019 07:45 am ET

Market Trends Toward New Normal in Agilent Technologies, Xilinx, Interpublic Group of Companies, Progenics Pharmaceuticals, Flexsteel Industries, and USA Truck — Emerging Consolidated Expectations, An

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Agilent Technologies, Inc. (NYSE:A), Xilinx, Inc. (NASDAQ:XLNX),...

Jan 03, 2019 01:30 am ET

Progenics and Curium Announce European Collaboration for Prostate Cancer Imaging Agent PyL™

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, and Curium today announced an exclusive agreement to develop and commercialize PyL...

Jan 02, 2019 08:30 am ET

Progenics Pharmaceuticals Expands Leadership Team with Appointment of Asha Das, M.D. as Chief Medical Officer

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced the appointment of Asha Das, M.D. to the newly created role of...

Dec 03, 2018 08:30 am ET

Progenics Doses First Patient in Pivotal Phase 3 Study of PyL, PSMA PET Imaging Agent, for the Detection of Prostate Cancer

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that the first patient has been dosed in the Company’s Phase 3...

Nov 28, 2018 07:30 am ET

Research Report Identifies Capstone Turbine, LivePerson, Diamondback Energy, Presidio, Pretium Resources, and Progenics Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Capstone Turbine Corporation (NASDAQ:CPST), LivePerson, Inc....

Nov 19, 2018 04:30 pm ET

Progenics Pharmaceuticals Announces Presentation of Updated Safety and Tolerability Data for AZEDRA® (iobenguane I 131) at the Radiological Society of North America (RSNA) Annual Meeting

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that safety and tolerability data from a pooled analysis of four...

Nov 08, 2018 07:30 am ET

Progenics Pharmaceuticals Announces Third Quarter 2018 Financial Results And Business Update

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced financial results and provided a business update for the third quarter of 2018. “The third quarter was marked by multiple successes on the clinical and regulatory front, including the...

Nov 06, 2018 08:00 am ET

Progenics Pharmaceuticals to Present at Upcoming Investor Conferences

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that management will present at the following upcoming investor...

Nov 01, 2018 08:00 am ET

Progenics Pharmaceuticals Sets Third Quarter 2018 Financial Results and Business Update Call for November 8

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced today that it will host a conference call and webcast to review the...

Oct 18, 2018 08:25 am ET

Recent Analysis Shows Progenics Pharmaceuticals, Catabasis Pharmaceuticals, Warrior Met Coal, Preformed Line Products, Express, and Sanmina Market Influences — Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Progenics Pharmaceuticals Inc. (NASDAQ:PGNX), Catabasis...

Oct 11, 2018 04:01 pm ET

Progenics Advances 1095, PSMA-Targeted Therapeutic Candidate for the Treatment of Metastatic Prostate Cancer, into Phase 2 Clinical Development Following Discussions with the FDA

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced plans to advance I-131 1095, its PSMA-targeted therapeutic, into a...

Oct 09, 2018 08:30 am ET

Progenics Announces Publication of Pivotal Trial of AZEDRA® (iobenguane I 131) in The Journal of Nuclear Medicine

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that the Company’s pivotal trial of AZEDRA® (iobenguane I 131),...

Oct 05, 2018 07:30 am ET

Progenics Reports Results of Phase 2/3 Trial of PSMA PET Imaging Agent PyL for the Detection of Prostate Cancer

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced data from its OSPREY 2301 Study of PyLTM (18F-DCFPyL). PyL is the...

Sep 25, 2018 08:30 am ET

Progenics Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that Mark R. Baker, Chief Executive Officer, will present at the...

Sep 17, 2018 06:00 am ET

Progenics Announces Addition of AZEDRA® (iobenguane I 131) to National Comprehensive Cancer Network Guidelines for Pheochromocytoma and Paraganglioma

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced that AZEDRA® (iobenguane I 131), the Company’s radiotherapeutic,...

Sep 12, 2018 04:01 pm ET

Progenics Pharmaceuticals Reports Top Line Phase 3 Data for Prostate Cancer Imaging Agent 1404

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today announced top line data from its Phase 3 study of 1404, the Company’s...

Aug 27, 2018 07:55 am ET

Detailed Research: Economic Perspectives on The Michaels Companies, Glu Mobile, Natus Medical, Progenics Pharmaceuticals, QuinStreet, and Jaguar Health — What Drives Growth in Today's Competitive Land

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of The Michaels Companies, Inc. (NASDAQ:MIK), Glu Mobile Inc. (NASDAQ:GLUU),...

Aug 07, 2018 10:12 pm ET

Progenics Pharmaceuticals Announces Pricing of Public Offering of Common Stock

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today the pricing of an underwritten public offering of 9,090,909 primary shares of its common stock at a public offering price of $8.25 per share. The gross proceeds from the sale of the...

Aug 07, 2018 04:01 pm ET

Progenics Pharmaceuticals Announces Proposed Public Offering of Common Stock

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today that it is offering to sell shares of its common stock in an underwritten public offering pursuant to an effective shelf registration statement. The offering is subject to market...

Jul 31, 2018 04:30 pm ET

Following Azedra’s Approval, Progenics Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Update

Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced financial results and provided a business update for the second quarter of 2018. “We’re extremely proud of our recent accomplishments, most notably the FDA approval of...

Jul 30, 2018 09:46 pm ET

Progenics Pharmaceuticals Announces FDA Approval for AZEDRA® (iobenguane I 131) to Treat Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for AZEDRA (iobenguane I 131) 555 MBq/mL injection for intravenous use. AZEDRA, a...

Jun 26, 2018 08:30 am ET

Progenics Pharmaceuticals Completes Enrollment of Phase 2/3 Clinical Trial of PSMA-Targeted PET/CT Imaging Agent PyL™ in Prostate Cancer

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging technology for targeting and treating cancer, today announced that it has completed enrollment in its Phase 2/3 OSPREY clinical trial...

Jun 25, 2018 08:30 am ET

Progenics Pharmaceuticals Presents Data Validating its Artificial Intelligence Imaging Analysis Technology for Use with PSMA-Targeted SPECT/CT

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging technology for targeting and treating cancer, reported data demonstrating the utility of its imaging analysis technology, which uses...

Jun 21, 2018 08:15 am ET

New Research: Key Drivers of Growth for Five Below, Progenics Pharmaceuticals, Advanced Micro Devices, Agilysys, Altair Engineering, and Semtech — Factors of Influence, Major Initiatives and Sustained

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Five Below, Inc. (NASDAQ:FIVE), Progenics Pharmaceuticals Inc....

Jun 08, 2018 07:00 am ET

Amicus Therapeutics Appoints President and COO Bradley L. Campbell to Board of Directors

Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare metabolic diseases, today announced the election and appointment of the Company’s President and Chief...

Jun 04, 2018 08:30 am ET

Progenics Pharmaceuticals Announces Presentation of Updated Data from the Pivotal Trial of AZEDRA® (iobenguane I 131) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced updated overall survival data from the Company’s pivotal Phase 2 trial of its...

May 31, 2018 08:45 am ET

Progenics Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging technology for targeting and treating cancer, announced today that Mark R. Baker, Chief Executive Officer, will present at the Jefferies...

May 31, 2018 08:30 am ET

Progenics’ Artificial Intelligence Technology for Automated Analysis of PSMA Targeted Prostate Cancer Images to be Featured at the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging technology for targeting and treating cancer, announced today that an abstract describing the Company’s imaging analysis technology will...

May 22, 2018 08:30 am ET

Progenics Announces JAMA Oncology Publication Highlighting Company’s Imaging Analysis Platform

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that results from a trial evaluating the use of its automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC) have been published online in...

May 09, 2018 07:30 am ET

Progenics Pharmaceuticals Announces First Quarter 2018 Financial Results and Business Update

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced financial results and provided a business update for the first quarter of 2018. “We continue with our preparations for the potential launch of AZEDRA in anticipation of our July 30th...

May 02, 2018 08:05 pm ET

Summary Judgment Granted Upholding the Validity of Formulation Patent Protecting RELISTOR® Injection

Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) reported that its partner Valeant Pharmaceuticals International, Inc. today announced that the U.S. District Court for the District of New Jersey has granted a motion for partial summary judgment of...

May 01, 2018 08:20 am ET

Research Report Identifies Cracker Barrel Old Country Store, Enova International, Natera, Inovalon, UMH Properties, and Progenics Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculati

NEW YORK, May 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Cracker Barrel Old Country Store, Inc....

Apr 26, 2018 08:30 am ET

Progenics Pharmaceuticals Sets First Quarter 2018 Financial Results Call for May 9

NEW YORK, April 26, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that it will host a conference call and webcast...

Apr 25, 2018 05:00 pm ET

Progenics Pharmaceuticals Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Pivotal Phase 2 AZEDRA Data Selected for Oral Presentation

Apr 02, 2018 08:30 am ET

Progenics Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference

NEW YORK, April 02, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced today that Mark R. Baker, Chief Executive Officer, will present...

Mar 22, 2018 04:15 pm ET

Progenics Pharmaceuticals Announces Three-Month Extension of PDUFA Date for AZEDRA® (iobenguane I 131)

NEW YORK, March 22, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced today that the Company has received notification from the U.S. Food...

Mar 20, 2018 08:30 am ET

Progenics Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference

NEW YORK, March 20, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced today that Mark R. Baker, Chief Executive Officer, will present...

Mar 19, 2018 08:30 am ET

Progenics Pharmaceuticals Announces Presentation of AZEDRA® (iobenguane I 131) Biochemical Tumor Marker Data at the 2018 Endocrine Society (ENDO) Annual Meeting

Significant correlation between overall tumor biomarker response and achievement of the primary and secondary endpoints in pivotal study of AZEDRA

Mar 08, 2018 07:45 am ET

Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2017 Financial Results and Business Update

NEW YORK, March 08, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced financial results and provided a business update for the fourth quarter and full-year 2017.

Mar 01, 2018 08:00 am ET

Progenics Pharmaceuticals Sets Fourth Quarter and Year-End 2017 Financial Results Call for March 8

NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced today that it will host a conference call and webcast...

Mar 01, 2018 07:35 am ET

Analysis: Positioning to Benefit within Penumbra, Qualys, OraSure Technologies, Air Lease, Aduro Biotech, and Progenics Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Penumbra, Inc. (NYSE:PEN), Qualys, Inc. (NASDAQ:QLYS),...

Feb 15, 2018 04:30 pm ET

Progenics Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare Conference

NEW YORK, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced today that Mark R. Baker, Chief Executive Officer, will present at...

Feb 05, 2018 08:30 am ET

Progenics Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference

NEW YORK, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that Patrick Fabbio, Chief Financial Officer, will present at...

Feb 01, 2018 04:45 pm ET

Progenics Pharmaceuticals Announces Presentation of AZEDRA® (iobenguane I 131) Biochemical Tumor Marker Data at the 2018 Endocrine Society (ENDO) Annual Meeting

NEW YORK, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, today announced that data from the Company’s open-label pivotal Phase 2b...

Jan 05, 2018 07:30 am ET

Report: Developing Opportunities within Aduro Biotech, Progenics Pharmaceuticals, Gevo, OSI, Senseonics, and Donnelley Financial Solutions — Future Expectations, Projections Moving into 2018

NEW YORK, Jan. 05, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aduro Biotech, Inc. (NASDAQ:ADRO), Progenics Pharmaceuticals...

Jan 02, 2018 08:30 am ET

Progenics Pharmaceuticals Completes Enrollment in Phase 3 Study of PSMA-Targeted Imaging Agent 1404

Top-line Data Expected in 3Q2018

Dec 29, 2017 08:30 am ET

Progenics Pharmaceuticals Announces FDA Acceptance of New Drug Application for AZEDRA® (iobenguane I 131) in Pheochromocytoma and Paraganglioma

NEW YORK, Dec. 29, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that the U.S. Food and Drug Administration (FDA) has accepted for...

Nov 02, 2017 08:00 am ET

Progenics Pharmaceuticals Announces Third Quarter 2017 Financial Results and Business Update

NEW YORK , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced financial results and provided a business update for the third quarter of 2017.

Nov 02, 2017 07:45 am ET

Progenics Pharmaceuticals Completes Submission of NDA for AZEDRA® (iobenguane I 131) in Pheochromocytoma and Paraganglioma

NEW YORK, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, announced today that it has completed the rolling submission of its...

Sep 01, 2017 05:18 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Progenics Pharmaceuticals Inc. - PGNX

NEW YORK, Sept. 1, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Progenics Pharmaceuticals Inc. ("Progenics" or the "Company") (NASDAQ: PGNX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980.

Aug 31, 2017 04:07 pm ET

Progenics Pharmaceuticals Presents Data from AZEDRA® Pivotal Phase 2b Study at the 5th International Symposium on Pheochromocytoma and Paraganglioma

NEW YORK, NY, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced that additional clinical data from the Company’s pivotal Phase 2b trial of its novel radiotherapeutic candidate, AZEDRA® (iobenguane I 131), in patients with malignant, recurrent, or unresectable pheochromocytoma and paraganglioma (pheo/para) will be presented at the 5th International Symposium on Pheochromocytoma and Paraganglioma in Sydney, Australia. AZEDRA has not been appro...

Aug 31, 2017 04:05 pm ET

Progenics Pharmaceuticals Provides Update on Timing of NDA Submission for AZEDRA®

- All Sections of New Drug Application (NDA) Have Been Submitted to the FDA, Except Notification of Pre-Approval Inspection Readiness -...

Jun 01, 2017 04:30 pm ET

Progenics Pharmaceuticals to Present at the Jefferies 2017 Global Healthcare Conference

NEW YORK, June 01, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that Mark R. Baker, Chief Executive Officer, will present at the Jefferies 2017 Global Healthcare Conference in New York City on Thursday, June 8, 2017 at 10:30 a.m. Eastern Time....

May 04, 2017 08:00 am ET

Progenics Pharmaceuticals Announces First Quarter 2017 Financial Results and Business Update

...

Apr 27, 2017 04:30 pm ET

Progenics Pharmaceuticals Sets First Quarter 2017 Financial Results Call for May 4

NEW YORK, April 27, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that it will host a conference call and webcast to review the first quarter ended March 31, 2017 financial results on Thursday, May 4, 2017, at 8:30 a.m. ET....

Apr 20, 2017 04:05 pm ET

Progenics Pharmaceuticals Announces Presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

NEW YORK, April 20, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced that data from a prospective biomarker analysis of a Phase 3 study using Progenics’ automated bone scan index (aBSI) will be presented in an oral session at the upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from June 2-6, 2017 in Chicago, Illinois. In addition, a second abstract from a study on translating the Prostate Cancer Workin...

Mar 30, 2017 04:15 pm ET

Progenics Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference

NEW YORK, March 30, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that Mark R. Baker, CEO, will present at the 16th Annual Needham Healthcare Conference in New York City on Wednesday, April 5, 2017 at 10:00 a.m. Eastern Time....

Mar 09, 2017 07:30 am ET

Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2016 Financial Results and Business Update

Registrational Phase 2B Trial Topline Results for Ultra-Orphan Radiotherapeutic Candidate AZEDRA® Expected First Quarter 2017Independent DMC Recommended Continuation of Enrollment of Phase 3 Trial for Imaging Agent 1404Initiated Phase 2/3 Trial of PyL™ Imaging AgentIn February 2017, Initiated Phase 1 Trial of PSMA Targeted Therapeutic Candidate 1095Monetized Portion of RELISTOR Royalty Stream through $50 Million TransactionFourth Quarter 2016 RELISTOR (SC and Oral) Net Sales of $16 MillionNEW YORK, March 09, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announc...

Feb 23, 2017 08:30 am ET

Progenics Pharmaceuticals Sets Fourth Quarter and Year-End 2016 Financial Results Call for March 9

NEW YORK, Feb. 23, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that it will host a conference call and webcast to review the fourth quarter and year ended December 31, 2016 financial results on Thursday, March 9, 2017, at 8:30 a.m. ET....

Feb 15, 2017 06:47 pm ET

Progenics Pharmaceuticals and Shutterfly to Join S&P SmallCap 600

NEW YORK, Feb. 15, 2017 /PRNewswire/ -- Effective with this press release, S&P Dow Jones Indices will now reference index changes using an "effective at the open" date rather than an "after the close of trading" date which is current practice.

Dec 07, 2016 08:30 am ET

Progenics Pharmaceuticals Announces First Patient Dosed in Phase 2/3 Clinical Trial of PSMA-Targeted PET/CT Imaging Agent PyL™

NEW YORK, Dec. 07, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced that the first patient has been dosed in the Company’s Phase 2/3 clinical trial evaluating the diagnostic accuracy of its PSMA-targeted PET/CT imaging agent, 18F-DCFPyL (PyLTM). PyL was discovered by a team led by Martin G. Pomper, M.D., Ph.D., William R. Brody Professor of Radiology at the Center for Translational Molecular Imaging at the Johns Hopkins University School of Med...

Nov 07, 2016 07:55 am ET

Progenics Pharmaceuticals Announces Third Quarter 2016 Financial Results and Business Update

Received $50 Million Milestone Payment from Valeant Related to U.S. Approval of RELISTOR® TabletsCommercial Launch of RELISTOR® Tablets in September 2016On November 4th, Monetized Portion of RELISTOR Royalty Stream through $50 Million TransactionThird Quarter 2016 RELISTOR (SC and Oral) Net Sales of $22.1 MillionUltra-Orphan Radiotherapeutic Candidate AZEDRA® Registrational Trial Topline Results Expected First Quarter 2017Advancing Phase 3 Trial for 1404 Toward Interim Analysis by End of This YearOn Track to Initiate Phase 2/3 Trial of PyL™ Imaging Agent and Phase 1 Trial of 1095 This Year ...

Nov 07, 2016 07:45 am ET

Progenics Announces $50 Million RELISTOR® Royalty-Backed Financing

NEW YORK, Nov. 07, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced that its wholly-owned subsidiary MNTX Royalties Sub LLC has entered into a $50 million term loan agreement with a fund managed by HealthCare Royalty Partners (“HCR”) secured by, and to be repaid from, royalties from future sales of RELISTOR®. Under the terms of the loan agreement, the lenders have no recourse to Progenics Pharmaceuticals, Inc., the parent company or to any of its...

Oct 24, 2016 08:30 am ET

Progenics Pharmaceuticals Sets Third Quarter 2016 Financial Results Call for November 7

NEW YORK, Oct. 24, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that it will host a conference call and webcast to review the third quarter ended September 30, 2016 financial results on Monday, November 7, 2016, at 8:30 a.m. ET....

Oct 21, 2016 08:30 am ET

Progenics Pharmaceuticals to Present at the 23rd Annual Prostate Cancer Foundation Scientific Retreat

NEW YORK, Oct. 21, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced that Mark Baker, Chief Executive Officer, will speak at the 23rd Annual Prostate Cancer Foundation (PCF) Scientific Retreat in Carlsbad, California on Friday, October 28, 2016 at 4:50 pm PT. Mr. Baker will present on PyL™, the Company’s PSMA-targeted PET imaging agent, which is expected to enter Phase 2 clinical development by the end of this year....

Sep 07, 2016 08:30 am ET

Progenics Pharmaceuticals Announces Appointment of Bryce V. Tenbarge as Vice President of Commercial

NEW YORK, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced the appointment of Bryce V. Tenbarge as Vice President of Commercial, effective August 22, 2016. In this newly created role, Mr. Tenbarge will report to Mark Baker, Chief Executive Officer of Progenics, and will be responsible for leading all of the Company’s commercial activities. Mr. Tenbarge brings over fifteen years of experience in biopharmaceutical marketing, most recently ...

Sep 06, 2016 06:00 pm ET

Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets

LAVAL, Quebec, Sept. 6, 2016 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) ("Progenics") today announced the U.S. commercial launch of RELISTOR® (methylnaltrexone bromide) Tablets, which is now available for prescribing. RELISTOR Tablets (450 mg once daily) were approved by the U.S. Food and Drug Administration (FDA) for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain on July 19, 2016.

Sep 06, 2016 06:00 pm ET

Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved Relistor® Tablets

LAVAL, Quebec, Sept. 6, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) ("Progenics") today announced the U.S. commercial launch of RELISTOR® (methylnaltrexone bromide) Tablets, which is now available for prescribing. RELISTOR Tablets (450 mg once daily) were approved by the U.S. Food and Drug Administration (FDA) for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain on July 19, 2016.

Sep 02, 2016 08:30 am ET

Progenics Pharmaceuticals to Present at the 23rd Annual NewsMakers in the Biotech Industry Conference

NEW YORK, Sept. 02, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced that Patrick Fabbio, Senior Vice President and Chief Financial Officer, will present at BioCentury’s 23rd Annual NewsMakers in the Biotech Industry Conference on Friday, September 9, 2016 at 2:30 p.m. Eastern Time. The conference is being held at the Millennium Broadway Hotel & Conference Center in New York, NY....

Aug 04, 2016 07:30 am ET

Progenics Pharmaceuticals Announces Second Quarter 2016 Financial and Business Results

On July 19, the Company Announced FDA Approval of RELISTOR® Tablets, Triggering a $50 Million Milestone Ultra-Orphan Radiotherapeutic Candidate AZEDRA® Registrational Trial Topline Results Expected Between December 2016 and March 2017Licensed PSMA Antibody Technology to Bayer and Recognition of $5 Million in Upfront and Milestone RevenuePhase 3 Study Enrollment of PSMA-Targeted SPECT/CT Imaging Agent 1404 OngoingSecond Quarter 2016 RELISTOR Subcutaneous (SC) Net Sales of $15.9 MillionOn Track to Initiate Phase 2/3 Trial for PyLTM Imaging Agent and Phase 1 Trial For 1095 This Year NEW YORK,...

Jul 26, 2016 08:30 am ET

Progenics Receives $50 Million Milestone Payment Following FDA Approval of RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain

TARRYTOWN, N.Y., July 26, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that it has received a $50 million milestone payment from its worldwide collaboration partner, Valeant Pharmaceuticals International, Inc. (NYSE:VRX), resulting from the US Food and Drug Administration's marketing approval last week of RELISTOR® Tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain....

Jul 22, 2016 08:30 am ET

Progenics Pharmaceuticals Sets Second Quarter 2016 Financial Results Call for August 4

TARRYTOWN, N.Y., July 22, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that it will host a conference call and webcast to review the second quarter ended June 30, 2016 financial results on Thursday, August 4, 2016, at 8:30 a.m. ET....

Jul 19, 2016 07:04 pm ET

Valeant and Progenics Announce FDA Approves RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain

LAVAL, Quebec and TARRYTOWN, N.Y., July 19, 2016 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE & TSX: VRX) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that the U.S. Food and Drug Administration has approved RELISTOR® (methylnaltrexone bromide) Tablets for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain. Valeant expects to commence sales of RELISTOR Tablets in the U.S. in the third quarter of 2016.

Jul 19, 2016 07:04 pm ET

Valeant and Progenics Announce FDA Approves RELISTOR® Tablets for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-cancer Pain

LAVAL, Quebec and TARRYTOWN, N.Y., July 19, 2016 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE & TSX: VRX) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that the U.S. Food and Drug Administration has approved RELISTOR® (methylnaltrexone bromide) Tablets for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain. Valeant expects to commence sales of RELISTOR Tablets in the U.S. in the third quarter of 2016.

Jul 08, 2016 08:30 am ET

Progenics Pharmaceuticals to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference

TARRYTOWN, N.Y., July 08, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced that Mark R. Baker, Chief Executive Officer, will present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on Wednesday, July 13, 2016 at 2:30 p.m. Eastern Time. The conference is being held at the Le Parker Meridien Hotel in New York, NY....

Jun 13, 2016 08:00 am ET

Progenics Pharmaceuticals Announces Presentations on its Prostate Cancer Imaging Programs at SNMMI 2016

TARRYTOWN, N.Y., June 13, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) announced today that data from its 1404 and PyLTM prostate cancer imaging programs will be presented at the upcoming Society of Nuclear Medicine and Molecular Imaging 2016 Annual Meeting, taking place from June 11 – 15, 2016 in San Diego, California....

Jun 09, 2016 08:00 am ET

Bradley Campbell, President and COO of Amicus Therapeutics, elected to Progenics Board of Directors

TARRYTOWN, N.Y., June 09, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced the election of Bradley Campbell to the Company’s Board of Directors. Mr. Campbell brings to Progenics extensive experience in the biopharmaceutical industry, with particular expertise in the areas of corporate strategy, commercial operations and planning, business development and sales and marketing. He currently serves as President and Chief Operating Officer of Amicus Th...

Jun 02, 2016 08:30 am ET

Progenics Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference

TARRYTOWN, N.Y., June 02, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc., (Nasdaq:PGNX), an oncology company focused on developing innovative medicines and other products for targeting and treating cancer, announced today that Mark R. Baker, Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 11:30 a.m. Eastern Time. The conference is being held at the Grand Hyatt in New York, NY....

May 05, 2016 07:30 am ET

Progenics Pharmaceuticals Announces First Quarter 2016 Financial and Business Results

On May 2nd, the Company Announced It Had Granted Exclusive World-Wide Rights to Bayer to Develop and Commercialize Products Using Progenics’ PSMA Antibody Technology In Combination with Alpha-Emitting RadionuclidesEnrollment in Pivotal Phase 3 Study of PSMA-Targeted SPECT/CT Imaging Agent 1404 Ongoing in the U.S. and CanadaPyL Study Data to be Presented at the 2016 American Urological AssociationAZEDRA® Pivotal Phase 2b Trial Topline Results Expected Between December 2016 and March 2017On April 4th, Oral RELISTOR® PDUFA Date Was Set for July 19, 2016; Approval to Trigger $50 Million Milestone...

May 02, 2016 08:30 am ET

Progenics Licenses PSMA Antibody Technology to Bayer for Development of Alpha-Radiolabeled Therapeutic Antibodies

TARRYTOWN, N.Y., May 02, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced that it has granted an exclusive license to Bayer for the development and commercialization of therapeutic antibodies combining the Company’s prostate specific membrane antigen (PSMA) antibody technology with Bayer’s targeted thorium conjugate technology....

Apr 04, 2016 08:00 am ET

Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR

-Agency requests standard three-month extension to review additional solicited information-

Apr 04, 2016 08:00 am ET

Valeant and Progenics Announce PDUFA Date Extension for Oral RELISTOR

-Agency requests standard three-month extension to review additional solicited information-